At the heart of Taiwan’s biotech transformation, the Development Center for Biotechnology (DCB) is pioneering new frontiers in exosome and extracellular vesicle (EV) therapy. Backed by four decades of public-private collaboration, DCB is bridging science, industry, and regulation to propel Taiwan into the global biotech spotlight.
In a candid discussion, Dr. Tsai-Kun Li, DCB Vice President, shares how the center is:
- Supporting startups through co-development & contract services
- Advancing both upstream & downstream exosome technologies
- Championing regulatory frameworks in a globally underregulated space
- Advising firms to avoid overcrowded markets and aim for impactful, niche indications like eye and joint diseases
- Positioning Taiwan as a competitive CDMO hub with strengths in early-phase clinical trials
As exosome-based therapeutics gain global momentum, Dr. Li believes collaboration, clinical excellence, and regulatory readiness will be Taiwan’s edge. With a focus on scientific rigor and strategic targeting, DCB is helping biotech firms turn proof-of-concept into global success.
Read the full interview article here: https://bit.ly/4mvjkUk
